Table 1.
Clinical and pathological data of all TGCT patients and controls used in present study. TGCT, testicular germ cell tumour; GCNIS, germ cell neoplasia in situ; IGCCCG, International Germ Cell Cancer Collaborative Group; n.a, not applicable.
| clinicopathologic features | TGCT patients |
controls | |
|---|---|---|---|
| GCNIS-related cases | GCNIS-unrelated cases | ||
| patients, n | 103 | 16 | 15 |
| age median (range) | 31 (13–52) | 16 (1–35) | 49 (16–86) |
| histological subtype | |||
| seminoma | 68 | n.a. | n.a. |
| embryonal carcinoma | 5 | n.a. | n.a. |
| postpubertal-type yolk-sac | 0 | n.a. | n.a. |
| choriocarcinoma | 0 | n.a. | n.a. |
| postpubertal-type teratoma | 2 | n.a. | n.a. |
| mixed germ cell tumours: | 28 | n.a. | n.a. |
| seminoma components | 12 | n.a. | n.a. |
| embryonal carcinoma components | 17 | n.a. | n.a. |
| yolk-sac tumour components | 13 | n.a. | n.a. |
| choriocarcinoma components | 6 | n.a. | n.a. |
| teratoma components | 14 | n.a. | n.a. |
| prepubertal-type teratoma | n.a. | 12/16 | n.a. |
| prepubertal-type yolk-sac | n.a. | 4/16 | n.a. |
| group staging | |||
| I | 67 | n.a. | n.a. |
| II | 24 | n.a. | n.a. |
| III | 11 | n.a. | n.a. |
| prognostic-based staging (according to IGCCCG classification), for metastatic diseasea | |||
| not applicable (non-metastatic) | 67 | n.a. | n.a. |
| good | 26 | n.a. | n.a. |
| intermediate | 6 | n.a. | n.a. |
| poor | 4 | n.a. | n.a. |
aInformation was not available in some TGCT cases.